Toregem BioPharma
PrivateLast Round
Early Funding
May 19, 2026
Total Funding Raised
$22.53M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Toregem BioPharma operates in Healthcare & Life Sciences and is based in Kyoto. Its latest recorded funding round was an Early Funding round in May 2026.
Toregem BioPharma is a biopharmaceutical company developing regenerative therapeutics for tooth loss.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Toregem BioPharma Comparables
Compare Toregem BioPharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OrganTech Inc. | 65% | |
| HysensBio | 61% | |
| Air Water Inc. | 54% |
For institutional investors. Book with your work email.
Toregem BioPharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | May 19, 2026 | ||||
| Series B | Aug 30, 2024 | ||||
| Series A Extension | Jul 3, 2023 | ||||
| Series A | Mar 8, 2022 | ||||
| Seed | Apr 30, 2021 | ||||
Seed | May 12, 2020 |
For institutional investors. Book with your work email.
Toregem BioPharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Chushin Venture Capital | Early Funding |
| Tohoku University Venture Partners | Series B, Series A Extension |
| JIC Venture Growth Investments | Early Funding, Series B, Series A Extension |
| Kyoto Capital Partners | Series B |
| Miraidoa | Series A |
| Astellas Venture Management | Series B, Series A Extension, Series A |
| Mitsubishi UFJ Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors grew 35% MoM, reaching 20.4K.
- May 19, 2026
$5.3M raised from multiple venture capital firms.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 11, 2026
Toregem BioPharma Co. appoints Hiroki Wada as president and chief executive effective Aug 27th '26 as it prepares to move its experimental tooth-regeneration drug into a Phase IIa trial in Japan.
For institutional investors. Book with your work email.
Toregem BioPharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Toregem BioPharma's valuation, stock price, and market status.
Is Toregem BioPharma a public or private company?
Toregem BioPharma is a private company.
What is the current stock price of Toregem BioPharma?
Toregem BioPharma is a private company, so its shares have no public market price. Caplight tracks Toregem BioPharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Toregem BioPharma worth (valuation)?
Valuation information for Toregem BioPharma is not publicly available.
Can I buy Toregem BioPharma stock?
Toregem BioPharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Toregem BioPharma's last funding round?
Toregem BioPharma's most recent funding round was Early Funding on May 19, 2026.
Who are the main investors in Toregem BioPharma?
Key investors in Toregem BioPharma include Kyoto University Innovation Capital.
Will Toregem BioPharma IPO soon?
No public IPO plans have been announced for Toregem BioPharma.
How can I track Toregem BioPharma secondary market activity?
Caplight tracks bids, offers, and trades in Toregem BioPharma's shares on secondary markets.